Similarly, Powe et al., 2022 showed that Luteolin combined with Erlotinib, an EGFR inhibitor, decreased proliferation and induced apoptosis in glioblastoma cell lines overexpressing EGFR or glioma cells expressing truncated EGFR. The gene discussed is EGFR; the disease is central nervous system cancer.